U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H48N4O4S
Molecular Weight 644.866
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IBODUTANT

SMILES

CC1=CC=C2C=C(SC2=C1)C(=O)NC3(CCCC3)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)NCC5CCN(CC6CCOCC6)CC5

InChI

InChIKey=YQYSVMKCMIUCHY-WJOKGBTCSA-N
InChI=1S/C37H48N4O4S/c1-26-9-10-30-23-33(46-32(30)21-26)35(43)40-37(15-5-6-16-37)36(44)39-31(22-27-7-3-2-4-8-27)34(42)38-24-28-11-17-41(18-12-28)25-29-13-19-45-20-14-29/h2-4,7-10,21,23,28-29,31H,5-6,11-20,22,24-25H2,1H3,(H,38,42)(H,39,44)(H,40,43)/t31-/m1/s1

HIDE SMILES / InChI

Molecular Formula C37H48N4O4S
Molecular Weight 644.866
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Menarini was developing ibodutant (also known as MEN15596) as a selective neurokinin (NK) 2 and tachykinin receptor antagonist. It is known that tachykinins have been implicated in the pathophysiology of irritable bowel syndrome (IBS) with diarrhoea. Ibodutant was studied as a treatment for gastrointestinal disorders. A phase 2 trial completed in May 2012 with positive results. Ibodutant participated in a 52-week phase 3 in women with IBS with diarrhea, however, the study was terminated because of the negative results of the sister study NAK-06 and the low overall response rate at week 24.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P21452
Gene ID: 6865.0
Gene Symbol: TACR2
Target Organism: Homo sapiens (Human)
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Ibodutant 10 mg
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:30:04 GMT 2023
Edited
by admin
on Fri Dec 15 18:30:04 GMT 2023
Record UNII
1H7RSQ28BJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IBODUTANT
INN   WHO-DD  
INN  
Official Name English
Ibodutant [WHO-DD]
Common Name English
6-METHYL-N-(1-(((2R)-1-((1-(OXAN-4-YLMETHYL)PIPERIDIN-4- YL)METHYLAMINO)-1-OXO-3-PHENYLPROPAN-2-YL)CARBAMOYL)CYCLOPENTYL)-1-BENZOTHIOPHENE-2-CARBOXAMIDE
Systematic Name English
ibodutant [INN]
Common Name English
Code System Code Type Description
CAS
522664-63-7
Created by admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
PRIMARY
INN
8909
Created by admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
PRIMARY
PUBCHEM
11527495
Created by admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
PRIMARY
FDA UNII
1H7RSQ28BJ
Created by admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
PRIMARY
MESH
C556791
Created by admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
PRIMARY
WIKIPEDIA
IBODUTANT
Created by admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
PRIMARY
SMS_ID
300000037039
Created by admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
PRIMARY
ChEMBL
CHEMBL266125
Created by admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
PRIMARY
NCI_THESAURUS
C166502
Created by admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
PRIMARY
DRUG BANK
DB12042
Created by admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
PRIMARY
EPA CompTox
DTXSID20966639
Created by admin on Fri Dec 15 18:30:04 GMT 2023 , Edited by admin on Fri Dec 15 18:30:04 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY